Home / Deep Research / Urinary Bladder Small Cell Neuroendocrine Carcinoma

Urinary Bladder Small Cell Neuroendocrine Carcinoma

1. Disease Information

2026-05-11
Falcon MONDO:0004114 Model: Edison Scientific Literature 30 citations

1. Disease Information

1.1 Overview (what is the disease?)

Urinary bladder small cell neuroendocrine carcinoma (often termed small cell carcinoma of the bladder, SCCB/SCBC) is a rare, aggressive, poorly differentiated, high-grade neuroendocrine carcinoma of the urinary bladder that is histomorphologically similar to small cell carcinomas arising in other organs (notably lung). (akbulut2024updatesonurinary pages 1-3, simon2025smallcellcarcinoma pages 4-5)

It comprises <1% of bladder malignancies/cancers in multiple authoritative sources. (akbulut2024updatesonurinary pages 1-3, gu2024pd1blockadeplus pages 1-3, simon2025smallcellcarcinoma pages 1-2)

1.2 Synonyms / alternative names

1.3 Aggregated vs individual-patient sources

The evidence base for SCCB is predominantly aggregated/retrospective (population registries, retrospective cohorts, pathology reviews) because of rarity, with relatively few prospective trials. For example, SEER-based incidence analyses (dores2015apopulationbasedstudy pages 1-2) and population-based outcomes cohorts (British Columbia registry) (oh2021smallcellcarcinoma pages 1-2) contrast with smaller multi-center retrospective cohorts (n=20) (lu2024treatmentandsurvival pages 1-2) and early-phase prospective immunotherapy-combination trials (n=15) (gu2024pd1blockadeplus pages 1-3).

2. Etiology

2.1 Disease causal factors (mechanistic/biologic)

SCCB is frequently mixed with urothelial carcinoma (UC) and is widely interpreted as arising via divergent differentiation/transdifferentiation from a urothelial precursor, supported by overlap in genomic features with UC. (akbulut2024updatesonurinary pages 1-3, akbulut2024updatesonurinary pages 3-4)

Genetically, SCCB commonly shows inactivation of tumor suppressors TP53 and RB1, a recurring hallmark of small cell carcinomas. (gu2024pd1blockadeplus pages 1-3, akbulut2024updatesonurinary pages 3-4)

2.2 Risk factors

Evidence note: SEER-based epidemiology also notes marked male predominance for urinary bladder extrapulmonary small cell carcinoma (male/female IRR 4.91). (dores2015apopulationbasedstudy pages 1-2)

2.3 Protective factors

No evidence for genetic or environmental protective factors specific to SCCB was identified in the retrieved sources.

2.4 Gene–environment interactions

No explicit gene–environment interaction analyses for SCCB (e.g., specific variants interacting with smoking exposure) were identified in the retrieved sources.

3. Phenotypes (clinical presentation)

3.1 Common presenting features

SCCB often presents similarly to urothelial carcinoma, with hematuria as the dominant symptom. - The 2025 review reports gross or microscopic hematuria in 68%–90% of patients. (simon2025smallcellcarcinoma pages 4-5) - Additional urinary symptoms include dysuria and frequency; UTIs and suprapubic discomfort are also noted. (simon2025smallcellcarcinoma pages 4-5) - Many patients present with nodal or metastatic involvement at diagnosis in some series/reviews. (liao2024emerginginsightsin pages 1-2, simon2025smallcellcarcinoma pages 4-5)

3.2 Phenotype characteristics (onset, severity, progression)

3.3 HPO term suggestions (non-exhaustive)

(Ontology IDs are provided as standard mappings; the retrieved sources did not themselves provide HPO codes.) - Hematuria — HP:0000790 (supported by clinical presentation evidence) (simon2025smallcellcarcinoma pages 4-5) - Dysuria — HP:0100584 (simon2025smallcellcarcinoma pages 4-5) - Urinary frequency — HP:0000010 (simon2025smallcellcarcinoma pages 4-5) - Recurrent urinary tract infections — HP:0002719 (simon2025smallcellcarcinoma pages 4-5) - Bone pain (via bone metastasis) — HP:0002653 (metastatic patterns discussed) (lu2024treatmentandsurvival pages 1-2)

3.4 Quality-of-life impact

Specific validated HRQoL instruments (e.g., EQ-5D/SF-36) for SCCB were not found in the retrieved sources. Given frequent hematuria, urinary symptoms, and need for multimodal therapy (cystectomy/chemoradiation), significant QoL impact is expected, but this inference is not quantified in the evidence set.

4. Genetic / Molecular Information

4.1 Causal genes (germline)

No germline causal genes or Mendelian inheritance patterns are established for SCCB in the retrieved evidence; SCCB is primarily characterized as a somatic, acquired malignancy.

4.2 Somatic genomic alterations (pathogenic variants in tumors)

A 2024 pathology review summarizes SCCB genomic features including: - Frequent inactivating TP53 and RB1 mutations (tumor suppressor loss) (akbulut2024updatesonurinary pages 3-4) - TERT promoter mutations (akbulut2024updatesonurinary pages 3-4, simon2025smallcellcarcinoma pages 15-16) - Absence of FGFR3 alterations (contrasting with subsets of urothelial carcinoma) (akbulut2024updatesonurinary pages 3-4) - APOBEC mutational signature (akbulut2024updatesonurinary pages 3-4) - Alterations in epigenetic regulators ARID1A, KDM6A, CREBBP, EP300 (akbulut2024updatesonurinary pages 3-4) - Potentially targetable alterations: PIK3CA hotspot mutations and occasional ERBB2 amplification (akbulut2024updatesonurinary pages 3-4)

A mechanistic/biologic convergence across small cell carcinomas is also emphasized: the 2024 clinical trial report states small cell carcinomas across tissues share high rates of TP53 and RB1 inactivation. (gu2024pd1blockadeplus pages 1-3)

4.3 Epigenetic information

The 2024 pathology review reports that RB protein loss can sometimes reflect epigenetic RB1 silencing and highlights alterations in epigenetic regulators (ARID1A, KDM6A, CREBBP, EP300). (akbulut2024updatesonurinary pages 3-4)

4.4 Transcriptomic / expression programs

RNA/miRNA findings summarized in the pathology review include loss of urothelial differentiation, activation of neural/neuroendocrine programs, dysregulated EMT, and immune-suppressive/pro-metastatic expression profiles. (akbulut2024updatesonurinary pages 3-4)

4.5 Molecular subtypes (transcription-factor-defined)

SCCB heterogeneity has been stratified using transcription factors ASCL1, NEUROD1, POU2F3, with reported subgroup frequencies (ASCL1+ 34%, NEUROD1+ 23%, ASCL1+/NEUROD1+ 16%, POU2F3+ 21%, double-negative 6%). (akbulut2024updatesonurinary pages 3-4)

4.6 GO (biological process) and CL (cell type) term suggestions

(Not explicitly enumerated in the retrieved sources; provided as standard structured suggestions aligned to the evidence.) - GO: neuroendocrine differentiation (general); cell cycle dysregulation (TP53/RB1 loss); epithelial-to-mesenchymal transition (EMT) (akbulut2024updatesonurinary pages 3-4) - CL: epithelial cell (urothelial lineage) and neuroendocrine-like tumor cell state (akbulut2024updatesonurinary pages 3-4, akbulut2024updatesonurinary pages 1-3)

5. Environmental Information

5.1 Environmental/lifestyle factors

Smoking is repeatedly identified as a major modifiable risk factor for SCCB in contemporary reviews. (simon2025smallcellcarcinoma pages 1-2)

No specific occupational toxins, radiation exposures, or infectious triggers were identified in the retrieved SCCB-specific evidence.

6. Mechanism / Pathophysiology (causal chain)

6.1 High-level causal chain (evidence-supported)

  1. Urothelial precursor tumor (often conventional urothelial carcinoma component) (akbulut2024updatesonurinary pages 1-3)
  2. Acquisition/selection of a small-cell neuroendocrine differentiation program with characteristic morphology and neuroendocrine marker expression (CD56/synaptophysin/chromogranin/INSM1) (akbulut2024updatesonurinary pages 1-3)
  3. Underlying genomic drivers frequently include TP53/RB1 inactivation (cell-cycle checkpoint loss) and TERT promoter mutation (replicative immortality), plus epigenetic regulator alterations and APOBEC mutagenesis (akbulut2024updatesonurinary pages 3-4, gu2024pd1blockadeplus pages 1-3)
  4. Clinical consequence: rapid progression, early metastasis, transient chemosensitivity with relapse, and poor survival in advanced/extensive disease (gu2024pd1blockadeplus pages 1-3, liao2024emerginginsightsin pages 1-2)

7. Anatomical Structures Affected

7.1 Organ/tissue level

7.2 UBERON term suggestions

8. Temporal Development (natural history)

8.1 Onset pattern

Typically presents in older adults (median age ~73 in SEER-referenced cohorts). (simon2025smallcellcarcinoma pages 1-2, lu2024treatmentandsurvival pages 1-2)

8.2 Progression and staging concepts

SCCB is clinically staged using standard bladder cancer staging systems (AJCC TNM), and many expert sources also use a two-tier limited vs extensive framework analogous to small cell lung cancer for treatment planning. (lu2024treatmentandsurvival pages 1-2)

The disease often demonstrates initial chemotherapy responses but frequent relapse/progression, motivating multimodal therapy in non-metastatic disease. (gu2024pd1blockadeplus pages 1-3, oh2021smallcellcarcinoma pages 1-2)

9. Inheritance and Population

9.1 Epidemiology and incidence

9.2 Inheritance

SCCB is not described as an inherited disorder in the retrieved evidence; the molecular data emphasize somatic alterations (TP53, RB1, TERT promoter, etc.). (akbulut2024updatesonurinary pages 3-4, gu2024pd1blockadeplus pages 1-3)

10. Diagnostics

10.1 Biopsy and histopathology

Diagnosis is based on histology showing classic small cell morphology and supported by neuroendocrine-marker immunohistochemistry. (akbulut2024updatesonurinary pages 1-3)

10.2 Immunohistochemistry (IHC)

Typical neuroendocrine markers include CD56, synaptophysin, chromogranin, and INSM1. (akbulut2024updatesonurinary pages 1-3)

RB loss by IHC and abnormal p53 staining patterns consistent with TP53 alteration are frequent supportive findings. (akbulut2024updatesonurinary pages 1-3)

10.3 Imaging

Staging commonly uses contrast-enhanced CT and/or MRI. A consensus approach described in the 2024 cohort paper includes gadolinium-enhanced MRI or contrast-enhanced CT as part of staging and a limited vs extensive system analogous to SCLC. (lu2024treatmentandsurvival pages 1-2)

11. Outcome / Prognosis

11.1 Survival statistics (population-based and cohort)

  • In a British Columbia population-based analysis of localized SCBC (1985–2018; n=77), 5-year OS was 29% (radical cystectomy) vs 39% (radiation) (p=0.51). (oh2021smallcellcarcinoma pages 1-2)
  • In the same study, among guideline-concordant patients, 5-year OS was 56% (RC) vs 58% (chemoRT) (p=0.90), and 5-year CSS was 56% vs 71% (p=0.71). (oh2021smallcellcarcinoma pages 1-2)
  • In a 2024 multi-center Chinese non-metastatic SCCB cohort (n=20), reported outcomes were more favorable for radical local treatment: local treatment median OS 65.3 months vs radical treatment median OS not reached; 3-year OS 54% vs 75%. (lu2024treatmentandsurvival pages 1-2)
  • In extensive disease, the 2024 phase 1b trial background summarizes historical outcomes: median OS 7–13 months despite initial 40%–60% responses to etoposide/platinum. (gu2024pd1blockadeplus pages 1-3)

11.2 Prognostic factors

12. Treatment

12.1 Standard systemic therapy (real-world implementation)

Because of rarity, SCCB regimens are commonly extrapolated from small cell lung cancer, centered on platinum (cisplatin/carboplatin) + etoposide, used either as definitive systemic therapy in extensive disease or perioperatively/with chemoradiation in limited disease. (lu2024treatmentandsurvival pages 1-2, gu2024pd1blockadeplus pages 1-3, liao2024emerginginsightsin pages 1-2)

12.2 Multimodal local therapy (localized disease)

Authoritative population-based evidence indicates radical cystectomy and bladder-conserving chemoradiotherapy can yield comparable long-term outcomes in localized disease when delivered in guideline-consistent multimodal frameworks. (oh2021smallcellcarcinoma pages 1-2)

12.3 Immunotherapy and emerging combinations (recent developments, 2024)

A notable 2024 development is prospective evidence for adding PD-1 blockade to platinum chemotherapy: - Direct abstract quote: “We report a phase 1b study of pembrolizumab in combination with platinum-based chemotherapy in 15 patients with stage III-IV small cell bladder (cohort 1) or small cell/neuroendocrine prostate cancers (cohort 2). Overall response rate (ORR) is 43% with two-year overall survival (OS) rate of 86% (95% confidence interval [CI]: 0.63, 1.00) for cohort 1 and 57% (95% CI: 0.30, 1.00) for cohort 2.” (gu2024pd1blockadeplus pages 1-3) This trial also reported grade ≥3 adverse events in 40% with no treatment-related deaths and included extensive immune correlative analyses. (gu2024pd1blockadeplus pages 1-3)

12.4 Active clinical trials (real-world pipeline)

Evidence from ClinicalTrials.gov records in this run includes: - NCT05312671: Atezolizumab + platinum/etoposide followed by cystectomy (localized small cell/neuroendocrine bladder cancer). (NCT05312671 chunk 1) - NCT06091124 (NEOBLAST): Neoadjuvant adebrelimab + etoposide/cisplatin followed by radical cystectomy. (NCT06091124 chunk 1) - NCT06228066 (LASER): Lurbinectedin ± avelumab in metastatic SCCB/high-grade neuroendocrine urinary tract tumors after platinum/etoposide. (NCT06228066 chunk 1) - NCT06161532 (SMART): Sacituzumab govitecan ± atezolizumab in rare metastatic GU tumors including high-grade neuroendocrine carcinomas. (NCT06161532 chunk 1) - NCT00756639: Prophylactic cranial irradiation (PCI) in small cell carcinoma of the urothelium. (NCT00756639 chunk 1)

12.5 MAXO term suggestions (non-exhaustive)

  • Platinum-based chemotherapy (cisplatin/carboplatin + etoposide)
  • Radical cystectomy
  • Radiotherapy / chemoradiotherapy
  • Immune checkpoint inhibitor therapy (PD-1/PD-L1 blockade)

13. Prevention

13.1 Primary prevention

Given smoking is a major modifiable risk factor, tobacco cessation is the most evidence-supported preventive strategy referenced in SCCB-focused reviews. (simon2025smallcellcarcinoma pages 1-2)

No SCCB-specific screening or chemoprevention strategies were identified in the retrieved sources.

14. Other Species / Natural Disease

No naturally occurring SCCB analogs in non-human species were identified in the retrieved evidence.

15. Model Organisms

No SCCB-specific animal models or dedicated model organism resources were identified in the retrieved evidence set for this run.

Recent (2023–2024) and Foundational Evidence Summary Tables

The following evidence-map tables consolidate the most relevant studies and actionable diagnostic/treatment details available in this run.

Table (click to expand)
Citation (first author, year) Publication date/month Study type/data source Population (n; stage) Key findings (include incidence/survival/genomics) URL/DOI PMID
Dores, 2015 Mar 2015 Population-based SEER-13 epidemiology/survival study Small cell carcinoma cases in SEER 1992–2010; EPSCC n=2,438 overall; urinary bladder site-specific analyses; limited vs distant stage Urinary bladder was among the highest-incidence extrapulmonary small cell carcinoma sites (IR 0.7–0.8 per million person-years); bladder had strong male predominance (male/female IRR 4.91); incidence of urinary bladder small cell carcinoma increased with APC 6.75 during 1992–2010; distant-to-limited stage IRR for bladder was decreased (0.32–0.46); for nearly all sites with distant stage disease, 3-year relative survival was <10% (dores2015apopulationbasedstudy pages 1-2) https://doi.org/10.1186/s12885-015-1188-y
Oh, 2021 Sep 2021 online; Can Urol Assoc J 2022 Population-based cohort from British Columbia Localized SCBC treated with curative intent, n=77; RC n=33, RT n=44; analysis 2 compared RC vs chemoRT per consensus-guideline treatment Five-year OS was 29% (RC) vs 39% (RT), p=0.51; five-year CSS 35% (RC) vs 52% (RT), p=0.29. In guideline-concordant analysis, 5-year OS was 56% (RC) vs 58% (chemoRT), p=0.90; 5-year CSS 56% vs 71%, p=0.71. Lack of neoadjuvant chemotherapy was associated with worse OS; authors conclude RC and chemoRT offer similar outcomes and NAC should be considered (oh2021smallcellcarcinoma pages 1-2) https://doi.org/10.5489/cuaj.7411
Akbulut, 2024 Mar 2024 Narrative pathology/genomics review Urinary bladder neuroendocrine tumors; summarizes bladder SMC/LCNEC literature and molecular subgroup data Reviews that bladder SMC/LCNEC comprise <1% of bladder malignancies; most SMCs are pure or mixed with urothelial carcinoma. Histology: small cells with nuclear molding, high mitoses, necrosis/crush artifact. IHC: CD56, synaptophysin, chromogranin, INSM1; frequent RB loss and mutant-pattern p53. Molecularly, bladder SMC shows higher TMB than conventional urothelial carcinoma, frequent TP53/RB1 inactivation, TERT promoter mutations, APOBEC signature, no FGFR3 alterations, and alterations in ARID1A, KDM6A, CREBBP, EP300; potential targetable events include PIK3CA hotspots and occasional ERBB2 amplifications. Molecular subgroups reported using ASCL1/NEUROD1/POU2F3, with POU2F3 and PLCG2 associated with poorer PFS/OS (akbulut2024updatesonurinary pages 1-3, akbulut2024updatesonurinary pages 3-4) https://doi.org/10.1097/pap.0000000000000433
Liao, 2024 Jan 2024 ASCO Educational Book review/expert synthesis GU small-cell carcinomas; bladder-focused review drawing on retrospective series and guidelines States bladder SCC accounts for ~0.48%–2% of bladder cancers; usually presents with gross hematuria and in the majority with nodal/metastatic involvement (~70%). Pathology/IHC parallels SCLC with epithelial and neuroendocrine markers (chromogranin, synaptophysin, INSM1, CD56). Management is multimodal and extrapolated from SCLC, using platinum-based chemotherapy with surgery and/or radiation; untreated 5-year OS is reported as <10%, and advanced disease remains highly lethal (liao2024emerginginsightsin pages 1-2) https://doi.org/10.1200/edbk_430336
Gu, 2024 Nov 2024 Phase 1b clinical trial with correlative biomarker analyses 15 patients with stage III–IV small cell bladder (cohort 1) or small cell/neuroendocrine prostate cancer (cohort 2) receiving pembrolizumab + platinum chemotherapy In this mixed bladder/prostate neuroendocrine trial, ORR was 43%; 2-year OS was 86% in cohort 1 and 57% in cohort 2; grade ≥3 adverse events occurred in 40% with no treatment-related deaths. Introductory data summarize SCBC as <1% of bladder cancers, often mixed with urothelial carcinoma (up to 70%), with initial 40%–60% response to etoposide/platinum but median OS 7–13 months in extensive disease. Genomically, SCCs share high rates of TP53 and RB1 inactivation; correlative analyses included PD-L1, TMB, MSI, and targeted 648-gene somatic testing (gu2024pd1blockadeplus pages 1-3, gu2024pd1blockadeplus pages 6-9) https://doi.org/10.1016/j.xcrm.2024.101824
Lu, 2024 Oct 2024 Multi-institution retrospective cohort from China Non-metastatic SCCB, n=20; localized T1–2N0 n=10, locally advanced ≥T3 or N+ n=10 SCCB accounts for 0.5%–1.0% of bladder cancers; cites SEER trend from 0.3% to 0.6%, male:female 3:1, median age 73. In the cohort, 90% received chemotherapy (neoadjuvant n=5, adjuvant n=13). Median OS was 65.3 months for local treatment and not reached for radical treatment; 3-year OS 54% vs 75%, respectively. Median PFS was 13.8 months for local treatment and not reached for radical treatment. Review within paper notes historical large series with median OS 11–20.7 months and 3-year OS 33%–37% for all stages; common metastases are pelvic/retroperitoneal nodes, liver, and bone; guidelines recommend platinum/etoposide-based multimodality therapy (lu2024treatmentandsurvival pages 1-2, lu2024treatmentandsurvival pages 7-7) https://doi.org/10.1038/s41598-024-75512-z
Simon, 2025 Jun 2025 Comprehensive review of pathogenesis, presentation, and management Review of SCCB literature; includes institutional/series summaries rather than a single cohort Defines SCCB as a rare aggressive neuroendocrine malignancy accounting for <1% of bladder cancers; incidence rose from 0.05 to 0.14 per 100,000 between the 1990s and 2000s. Predominantly affects older men (77.8% male; median age 73). Smoking is the principal modifiable risk factor (50%–79% current/former smokers). Common presentation includes gross/microscopic hematuria (68%–90%), dysuria, frequency, suprapubic discomfort; paraneoplastic syndromes are rare. Pure SCCB represents about one-third of cases; most are mixed with urothelial carcinoma. Shared clonal origin with UC is supported by concordant TP53 mutations; review also notes frequent TP53/RB mutations, high TMB, and frequent TERT promoter mutation in SCCB (simon2025smallcellcarcinoma pages 1-2, simon2025smallcellcarcinoma pages 4-5, simon2025smallcellcarcinoma pages 15-16) https://doi.org/10.1177/23523735251370956

Table: This table compiles major recent and foundational studies/resources on urinary bladder small cell neuroendocrine carcinoma, emphasizing epidemiology, pathology/genomics, treatment, and survival. It is useful as a quick evidence map for building a disease knowledge base entry and identifying where recent advances complement older population-based outcome data.

Table (click to expand)
Domain Item (test/marker/therapy) Details Evidence type Key quantitative data Source (first author/year or NCT) URL/DOI
Diagnostic Histopathology Small-cell morphology: cells smaller than ~3 lymphocytes, high nuclear-to-cytoplasmic ratio, scant cytoplasm, inconspicuous nucleoli, vesicular chromatin, nuclear molding, frequent mitoses, geographic/single-cell necrosis, crush artifact; growth in solid sheets, trabeculae, acinar patterns (akbulut2024updatesonurinary pages 1-3) Review No single performance metric reported Akbulut 2024 https://doi.org/10.1097/pap.0000000000000433
Diagnostic Immunohistochemistry panel Typical neuroendocrine markers: CD56, synaptophysin, chromogranin, INSM1; keratin often limited/dot-like perinuclear in SMC; frequent RB loss by IHC and abnormal p53 staining supporting TP53 alteration (akbulut2024updatesonurinary pages 1-3) Review No sensitivity/specificity stated; Ki-67 described as high in SMC/LCNEC (akbulut2024updatesonurinary pages 1-3) Akbulut 2024 https://doi.org/10.1097/pap.0000000000000433
Diagnostic Expanded marker panel SCCB can express synaptophysin, chromogranin, INSM1, neuron-specific enolase, CD56, pancytokeratin, CK8, CK19; up to 40% may stain TTF-1; electron microscopy may show dense-core neurosecretory granules and desmosomes (simon2025smallcellcarcinoma pages 4-5, gu2024pd1blockadeplus pages 1-3) Review + trial background TTF-1 positivity up to 40% (simon2025smallcellcarcinoma pages 4-5) Simon 2025; Gu 2024 https://doi.org/10.1177/23523735251370956 ; https://doi.org/10.1016/j.xcrm.2024.101824
Diagnostic Molecular/IHC subtype markers Novel transcription-factor markers NEUROD1, ASCL1, POU2F3 identify subgroups; reported groups: ASCL1+ 34%, NEUROD1+ 23%, ASCL1+/NEUROD1+ 16%, POU2F3+ 21%, double-negative 6%; POU2F3 and PLCG2 associated with worse PFS/OS (akbulut2024updatesonurinary pages 3-4, akbulut2024updatesonurinary pages 1-3) Review Subtype proportions: 34%, 23%, 16%, 21%, 6%; PLCG2 expressed in 32% (akbulut2024updatesonurinary pages 3-4) Akbulut 2024 https://doi.org/10.1097/pap.0000000000000433
Diagnostic Imaging for staging Recommended staging includes gadolinium-enhanced MRI or contrast-enhanced CT; CT urography commonly used; whole-body FDG PET/CT mentioned for metastatic detection (lu2024treatmentandsurvival pages 1-2, simon2025smallcellcarcinoma pages 15-16) Cohort/review CT urography accuracy cited in review: 40%–92% for perivesical invasion and 40%–85% for nodal metastasis (simon2025smallcellcarcinoma pages 4-5) Lu 2024; Simon 2025 https://doi.org/10.1038/s41598-024-75512-z ; https://doi.org/10.1177/23523735251370956
Diagnostic Genomic profiling Frequent inactivating TP53 and RB1 mutations, TERT promoter mutations, higher tumor mutation burden than conventional urothelial carcinoma, APOBEC signature; additional alterations in ARID1A, KDM6A, CREBBP, EP300; occasional PIK3CA hotspot mutations and ERBB2 amplification (akbulut2024updatesonurinary pages 3-4, simon2025smallcellcarcinoma pages 15-16) Review No test performance metric reported Akbulut 2024; Simon 2025 https://doi.org/10.1097/pap.0000000000000433 ; https://doi.org/10.1177/23523735251370956
Treatment Platinum-etoposide systemic therapy Standard frontline approach extrapolated from SCLC: cisplatin or carboplatin plus etoposide for extensive disease; also used neoadjuvantly/adjuvantly in limited disease (lu2024treatmentandsurvival pages 1-2, liao2024emerginginsightsin pages 1-2, gu2024pd1blockadeplus pages 1-3) Guideline-informed review + cohort + trial background Initial response rate 40%–60% in SCBC; median OS 7–13 months in extensive disease (gu2024pd1blockadeplus pages 1-3) Liao 2024; Lu 2024; Gu 2024 https://doi.org/10.1200/edbk_430336 ; https://doi.org/10.1038/s41598-024-75512-z ; https://doi.org/10.1016/j.xcrm.2024.101824
Treatment Multimodal local therapy For limited/localized disease, reviews/guidelines support concurrent chemoradiotherapy or neoadjuvant chemotherapy followed by local treatment (radical cystectomy or radiotherapy) (lu2024treatmentandsurvival pages 1-2, oh2021smallcellcarcinoma pages 1-2) Cohort + guideline-informed review In BC population study, lack of neoadjuvant chemotherapy associated with worse OS; 5-year OS 56% RC vs 58% chemoRT in guideline-concordant patients (oh2021smallcellcarcinoma pages 1-2) Lu 2024; Oh 2021 https://doi.org/10.1038/s41598-024-75512-z ; https://doi.org/10.5489/cuaj.7411
Treatment Radical cystectomy (RC) Used after neoadjuvant chemotherapy or as radical local treatment in selected non-metastatic patients (lu2024treatmentandsurvival pages 1-2, oh2021smallcellcarcinoma pages 1-2) Cohort Five-year OS 29% and CSS 35% in all curative-intent RC patients; in guideline-concordant subgroup, 5-year OS 56% and CSS 56% (oh2021smallcellcarcinoma pages 1-2) Oh 2021 https://doi.org/10.5489/cuaj.7411
Treatment Definitive chemoradiotherapy / radiotherapy Curative-intent RT used with platinum-based chemotherapy for localized disease; consensus-guideline analysis used ~60 Gy EQD2; hypofractionated 45 Gy/15 fractions over 3 weeks and conventional 60–66 Gy regimens referenced; RT dose ≥54 Gy associated with improved OS in cited series (oh2021smallcellcarcinoma pages 1-2, lu2024treatmentandsurvival pages 7-7) Population cohort + retrospective synthesis Five-year OS 39% and CSS 52% for all RT patients; in guideline-concordant chemoRT subgroup, 5-year OS 58% and CSS 71% (oh2021smallcellcarcinoma pages 1-2); no OS difference between RC and RT in organ-confined disease in pooled data (26.7 vs 30.0 months) (lu2024treatmentandsurvival pages 7-7) Oh 2021; Lu 2024 https://doi.org/10.5489/cuaj.7411 ; https://doi.org/10.1038/s41598-024-75512-z
Treatment Chinese multi-center real-world treatment In non-metastatic SCCB, 90% received chemotherapy; 13 had local treatment (PC/TURBT), 7 radical treatment (RC/RT) (lu2024treatmentandsurvival pages 1-2) Cohort Local-treatment median OS 65.3 months; radical-treatment median OS not reached; 3-year OS 54% vs 75%; local-treatment median PFS 13.8 months; radical-treatment median PFS not reached (lu2024treatmentandsurvival pages 1-2) Lu 2024 https://doi.org/10.1038/s41598-024-75512-z
Treatment Pembrolizumab + platinum-based chemotherapy Phase 1b regimen for stage III-IV small cell bladder/prostate neuroendocrine cancers (trial registered NCT03582475); explored immunologic correlates with serial single-cell PBMC analyses (gu2024pd1blockadeplus pages 1-3, gu2024pd1blockadeplus pages 6-9) Prospective phase 1b trial ORR 43%; 2-year OS 86% in bladder cohort and 57% in prostate cohort; grade ≥3 adverse events 40%; no treatment-related deaths or cessation due to toxicity (gu2024pd1blockadeplus pages 1-3) Gu 2024 https://doi.org/10.1016/j.xcrm.2024.101824
Treatment Atezolizumab + platinum + etoposide followed by cystectomy Ongoing phase II trial in localized small cell/neuroendocrine bladder cancer; atezolizumab 1200 mg day 1 + etoposide 100 mg/m2 days 1–3 + cisplatin 70 mg/m2 day 1 or carboplatin AUC 5 day 1, every 21 days ×4; then cystectomy and atezolizumab maintenance up to 1 year (NCT05312671 chunk 1) ClinicalTrials.gov Enrollment 63 planned; primary endpoint pathologic complete response at cystectomy (NCT05312671 chunk 1) NCT05312671 https://clinicaltrials.gov/study/NCT05312671
Treatment Neoadjuvant adebrelimab + etoposide + cisplatin followed by radical cystectomy Ongoing phase II single-arm study for neuroendocrine bladder carcinoma; adebrelimab 1200 mg day 1 + etoposide 0.1 g days 1–3 + cisplatin 35 mg/m2 days 1–2 every 21 days for up to 4 cycles, then RC (NCT06091124 chunk 1) ClinicalTrials.gov Enrollment 22 planned; primary endpoints: ypCR and safety/tolerability (NCT06091124 chunk 1) NCT06091124 https://clinicaltrials.gov/study/NCT06091124
Treatment Lurbinectedin ± avelumab (LASER) Ongoing phase II study in metastatic SCCB/HGNET after prior platinum/etoposide or ineligible/refused; lurbinectedin 3.2 mg/m2 IV q21d ± avelumab 800 mg IV q21d (NCT06228066 chunk 1) ClinicalTrials.gov Enrollment 45 planned; primary endpoint ORR; background notes average survival about 1 year and lurbinectedin ORR 35% in second-line SCLC (NCT06228066 chunk 1) NCT06228066 https://clinicaltrials.gov/study/NCT06228066
Treatment Sacituzumab govitecan ± atezolizumab (SMART) Ongoing phase II in rare metastatic GU tumors including high-grade neuroendocrine bladder/urinary tract cancers; sacituzumab govitecan 10 mg/kg IV days 1 and 8 q21d ± atezolizumab 1200 mg day 1 q21d (NCT06161532 chunk 1) ClinicalTrials.gov Enrollment 60 planned; primary endpoint ORR (NCT06161532 chunk 1) NCT06161532 https://clinicaltrials.gov/study/NCT06161532
Treatment Prophylactic cranial irradiation (PCI) Phase II MD Anderson study of whole-brain RT after chemotherapy/surgery in locally advanced/metastatic small cell carcinoma of the urothelium; PCI 30 Gy in 2 Gy fractions over 3 weeks (NCT00756639 chunk 1) ClinicalTrials.gov Enrollment 31 actual; primary endpoint brain-metastasis-free survival at 1 year (NCT00756639 chunk 1) NCT00756639 https://clinicaltrials.gov/study/NCT00756639

Table: This table summarizes evidence-supported diagnostic modalities and current treatment approaches for urinary bladder small cell neuroendocrine carcinoma, including marker panels, staging tools, standard multimodal therapy, and active clinical trials. It is useful as a compact evidence map for clinical and knowledge-base curation.

Abstract-Supported Key Statistics and Direct Quotes (selected)

  1. SEER EPSCC incidence and trends (direct abstract quote): “Of the EPSCC sites, urinary bladder, prostate, and uterine cervix had the highest incidence (IRs = 0.7-0.8)… During 1992–2010, significant changes in IRs were observed for… small cell carcinoma of the urinary bladder (APC = 6.75).” (dores2015apopulationbasedstudy pages 1-2)

  2. Prospective immunotherapy + chemotherapy signal (direct abstract quote): “Overall response rate (ORR) is 43% with two-year overall survival (OS) rate of 86%… for cohort 1…” (pembrolizumab + platinum; SCBC cohort). (gu2024pd1blockadeplus pages 1-3)

  3. Non-metastatic multi-center China cohort (direct abstract quote): “A total of 20 patients were included… A total of 18 patients (90%) received chemotherapy… The median OS for the receiving local treatment was 65.3 months… The median OS for the receiving radical treatment was not reached…” (lu2024treatmentandsurvival pages 1-2)

Expert synthesis / analysis (evidence-based)

Across recent authoritative pathology and oncology sources, SCCB is best conceptualized as a urothelial-lineage malignancy that adopts a small-cell neuroendocrine state, driven by recurrent TP53/RB1 loss and associated molecular programs (loss of urothelial differentiation and activation of neural/neuroendocrine transcriptional programs). (akbulut2024updatesonurinary pages 3-4, akbulut2024updatesonurinary pages 1-3, gu2024pd1blockadeplus pages 1-3)

Clinically, the strongest real-world management pattern is multimodal therapy (platinum-etoposide-based systemic therapy integrated with cystectomy or chemoradiation), with population-based evidence showing comparable long-term survival for guideline-concordant cystectomy-based vs chemoRT-based strategies in localized disease. (oh2021smallcellcarcinoma pages 1-2)

The most notable 2024 therapeutic development in the retrieved evidence is early-phase prospective support for checkpoint blockade combined with platinum chemotherapy, which—if validated—could shift frontline systemic therapy for advanced SCCB toward immunochemotherapy paradigms similar to small cell lung cancer. (gu2024pd1blockadeplus pages 1-3)

References

  1. (akbulut2024updatesonurinary pages 1-3): Dilara Akbulut and Hikmat Al-Ahmadie. Updates on urinary bladder tumors with neuroendocrine features. Advances In Anatomic Pathology, 31:169-177, Mar 2024. URL: https://doi.org/10.1097/pap.0000000000000433, doi:10.1097/pap.0000000000000433. This article has 12 citations and is from a domain leading peer-reviewed journal.

  2. (simon2025smallcellcarcinoma pages 4-5): Nicholas I Simon, Andre R Kydd, Dilara Akbulut, David Takeda, Jaydira Del Rivero, Maria Merino, Bernadette Redd, Liza Lindenberg, Esther Mena, Elias Chandran, Sandeep Gurram, Salah Boudjadi, Scot Niglio, Parth Sharma, Anish Thomas, and Andrea B Apolo. Small cell carcinoma of the bladder: review of pathogenesis, presentation, and management. Bladder Cancer, Jun 2025. URL: https://doi.org/10.1177/23523735251370956, doi:10.1177/23523735251370956. This article has 1 citations.

  3. (gu2024pd1blockadeplus pages 1-3): Yiqian Gu, Ann Ly, Sara Rodriguez, Hanwei Zhang, Jiyoon Kim, Zhiyuan Mao, Ankush Sachdeva, Nazy Zomorodian, Matteo Pellegrini, Gang Li, Sandy Liu, Alexandra Drakaki, Matthew B. Rettig, and Arnold I. Chin. Pd-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers. Cell Reports Medicine, 5:101824, Nov 2024. URL: https://doi.org/10.1016/j.xcrm.2024.101824, doi:10.1016/j.xcrm.2024.101824. This article has 16 citations and is from a peer-reviewed journal.

  4. (simon2025smallcellcarcinoma pages 1-2): Nicholas I Simon, Andre R Kydd, Dilara Akbulut, David Takeda, Jaydira Del Rivero, Maria Merino, Bernadette Redd, Liza Lindenberg, Esther Mena, Elias Chandran, Sandeep Gurram, Salah Boudjadi, Scot Niglio, Parth Sharma, Anish Thomas, and Andrea B Apolo. Small cell carcinoma of the bladder: review of pathogenesis, presentation, and management. Bladder Cancer, Jun 2025. URL: https://doi.org/10.1177/23523735251370956, doi:10.1177/23523735251370956. This article has 1 citations.

  5. (lu2024treatmentandsurvival pages 1-2): Jiawei Lu, Jiaomei Zhou, Yueping Liu, Yexiong Li, Yuan Tang, Ning Li, Shulian Wang, Yongwen Song, Wenjue Zhang, Xiaoyong Xiang, and Jing Jin. Treatment and survival of non-metastatic small cell carcinoma of the bladder from multiple centers in china. Scientific Reports, Oct 2024. URL: https://doi.org/10.1038/s41598-024-75512-z, doi:10.1038/s41598-024-75512-z. This article has 3 citations and is from a peer-reviewed journal.

  6. (oh2021smallcellcarcinoma pages 1-2): Justin Oh, Bernhard Eigl, Peter C. Black, Tom Pickles, Carlos Villamil, Katherine Sunderland, and Scott Tyldesley. Small cell carcinoma of the bladder: a population-based analysis of long-term outcomes after radical cystectomy and bladder conservation with chemoradiotherapy. Canadian Urological Association Journal, Jul 2021. URL: https://doi.org/10.5489/cuaj.7411, doi:10.5489/cuaj.7411. This article has 0 citations.

  7. (NCT05312671 chunk 1): Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. 2022. ClinicalTrials.gov Identifier: NCT05312671

  8. (NCT06091124 chunk 1): Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma. RenJi Hospital. 2023. ClinicalTrials.gov Identifier: NCT06091124

  9. (NCT06228066 chunk 1): Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER). National Cancer Institute (NCI). 2024. ClinicalTrials.gov Identifier: NCT06228066

  10. (dores2015apopulationbasedstudy pages 1-2): Graça M Dores, Osama Qubaiah, Ankur Mody, Bassam Ghabach, and Susan S Devesa. A population-based study of incidence and patient survival of small cell carcinoma in the united states, 1992–2010. BMC Cancer, Mar 2015. URL: https://doi.org/10.1186/s12885-015-1188-y, doi:10.1186/s12885-015-1188-y. This article has 54 citations and is from a peer-reviewed journal.

  11. (akbulut2024updatesonurinary pages 3-4): Dilara Akbulut and Hikmat Al-Ahmadie. Updates on urinary bladder tumors with neuroendocrine features. Advances In Anatomic Pathology, 31:169-177, Mar 2024. URL: https://doi.org/10.1097/pap.0000000000000433, doi:10.1097/pap.0000000000000433. This article has 12 citations and is from a domain leading peer-reviewed journal.

  12. (liao2024emerginginsightsin pages 1-2): Ross S. Liao, Hui Ting Ruan, Albert Jang, Melissa Huynh, Rosa Nadal Rios, Jean H. Hoffman-Censits, Shuanzeng Wei, Omar Y. Mian, and Pedro C. Barata. Emerging insights in small-cell carcinoma of the genitourinary tract: from diagnosis to novel therapeutic horizons. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 44:e430336, Jan 2024. URL: https://doi.org/10.1200/edbk_430336, doi:10.1200/edbk_430336. This article has 12 citations.

  13. (simon2025smallcellcarcinoma pages 15-16): Nicholas I Simon, Andre R Kydd, Dilara Akbulut, David Takeda, Jaydira Del Rivero, Maria Merino, Bernadette Redd, Liza Lindenberg, Esther Mena, Elias Chandran, Sandeep Gurram, Salah Boudjadi, Scot Niglio, Parth Sharma, Anish Thomas, and Andrea B Apolo. Small cell carcinoma of the bladder: review of pathogenesis, presentation, and management. Bladder Cancer, Jun 2025. URL: https://doi.org/10.1177/23523735251370956, doi:10.1177/23523735251370956. This article has 1 citations.

  14. (NCT06161532 chunk 1): Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C.... National Cancer Institute (NCI). 2024. ClinicalTrials.gov Identifier: NCT06161532

  15. (NCT00756639 chunk 1): Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium. M.D. Anderson Cancer Center. 2008. ClinicalTrials.gov Identifier: NCT00756639

  16. (gu2024pd1blockadeplus pages 6-9): Yiqian Gu, Ann Ly, Sara Rodriguez, Hanwei Zhang, Jiyoon Kim, Zhiyuan Mao, Ankush Sachdeva, Nazy Zomorodian, Matteo Pellegrini, Gang Li, Sandy Liu, Alexandra Drakaki, Matthew B. Rettig, and Arnold I. Chin. Pd-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers. Cell Reports Medicine, 5:101824, Nov 2024. URL: https://doi.org/10.1016/j.xcrm.2024.101824, doi:10.1016/j.xcrm.2024.101824. This article has 16 citations and is from a peer-reviewed journal.

  17. (lu2024treatmentandsurvival pages 7-7): Jiawei Lu, Jiaomei Zhou, Yueping Liu, Yexiong Li, Yuan Tang, Ning Li, Shulian Wang, Yongwen Song, Wenjue Zhang, Xiaoyong Xiang, and Jing Jin. Treatment and survival of non-metastatic small cell carcinoma of the bladder from multiple centers in china. Scientific Reports, Oct 2024. URL: https://doi.org/10.1038/s41598-024-75512-z, doi:10.1038/s41598-024-75512-z. This article has 3 citations and is from a peer-reviewed journal.